Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma

• Published in: Experimental & molecular medicine 2020, 52(0), , pp.1-11
• Main Authors: Koo, Seo-Young, Park, Eun-Ji, Lee, Chang-Woo
• Format: Article
• Language: English
• Subjects: 13/21; 13/51; 13/95; 631/250/1933; 64/60; 692/699/249; 82/51; 82/79; 82/80; 96/63; Animals; Biomedical and Life Sciences; Biomedicine; Carcinoma, Hepatocellular - immunology; Carcinoma, Hepatocellular - pathology; Disease Progression; Fatty liver; Fibrosis; Hepatocellular carcinoma; Hepatocytes; Humans; Immune response; Immune system; Immunology; Immunoregulation; Inflammation; Liver cancer; Liver diseases; Liver Neoplasms - immunology; Liver Neoplasms - pathology; Medical Biochemistry; Microenvironments; Models, Biological; Molecular Medicine; Non-alcoholic Fatty Liver Disease - immunology; Review; Review Article; Risk factors; Steatosis; Stem Cells; Tumor Microenvironment; 생화학
• ISSN: 1226-3613; 2092-6413
• DOI: 10.1038/s12276-020-0480-3

Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease, ranges from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), which is a more aggressive form characterized by hepatocyte injury, inflammation, and fibrosis. Increasing evidence suggests that NASH is a risk factor for hepatocellular carcinoma (HCC), which is the fifth most common cancer worldwide and the second most common cause of cancer-related death. Recent studies support a strong mechanistic link between the NASH microenvironment and HCC development. The liver has a large capacity to remove circulating pathogens and gut-derived microbial compounds. Thus, the liver is a central player in immunoregulation. Altered immune responses are tightly associated with the development of NASH and HCC. The objective of this study was to differentiate the roles of specific immune cell subsets in NASH and HCC pathogenesis. Liver disease: Immune cells in disease progression Clarifying the role of specific cells in the immune system in the transition from non-alcoholic fatty liver disease (NAFLD) to liver cancer will help to understand disease progression and may open avenues towards new preventive and therapeutic strategies. NAFLD is the most common chronic liver disease. Growing evidence suggests that its most aggressive form, non-alcoholic steatohepatitis (NASH), can promote the development of liver cancer, the second most common cause of cancer deaths worldwide. Chang-Woo Lee and colleagues at Sungkyunkwan University, Suwon, South Korea review the immunological distinction between NASH and liver cancer, focusing on the levels and activities of six key types of immune system cells. Chronic inflammation mediated by the immune system can create conditions for NAFLD, NASH and liver cancer to develop and worsen.